A new bispecific antibody targeting HER2-positive gastroesophageal cancer has demonstrated significant survival benefits in a phase III trial, according to research published in The New England Journal of Medicine. The HERIZON-GEA-01 study showed zanidatamab plus chemotherapy reduced the risk of disease progression or death by 44% compared to trastuzumab plus chemotherapy in patients with previously untreated HER2-positive gastroesophageal adenocarcinoma.
Progression-Free Survival Outcomes by Treatment Group
Percentage of patients progression-free at key timepoints, HERIZON-GEA-01 trial
Source: NEJM, 2026 | Georgian Medical Journal News
Dual HER2 targeting mechanism shows clinical promise
The HERIZON-GEA-01 trial enrolled 710 patients across multiple international sites to compare zanidatamab with the current standard of care. Zanidatamab is a bispecific antibody that simultaneously targets two distinct epitopes on the HER2 receptor.
Patients receiving zanidatamab plus chemotherapy achieved a median progression-free survival of 12.5 months compared to 8.5 months for those treated with trastuzumab plus chemotherapy. The hazard ratio of 0.56 (95% CI, 0.45-0.70) represented a statistically significant improvement according to the HERIZON-GEA-01 study results.
Safety profile remains manageable
The safety analysis revealed that zanidatamab was generally well-tolerated, with a manageable adverse event profile according to the NEJM study. The most common grade 3 or higher adverse events in the zanidatamab group included neutropenia, anemia, and diarrhea.
The incidence of cardiac dysfunction—a known concern with HER2-targeted therapies—was low in both treatment arms according to the trial results. This finding supports the potential for broader clinical application of zanidatamab in patients who might be at risk for cardiac complications with existing HER2-targeted treatments.
Global implications for gastric cancer treatment
The study’s international scope, including sites across Asia, Europe, and the Americas, strengthens the generalizability of the findings according to the HERIZON-GEA-01 investigators. This geographic diversity is particularly important given the known regional variations in gastroesophageal cancer biology and treatment outcomes.
Regulatory pathway and clinical implementation
The robust efficacy signal demonstrated in this phase III trial positions zanidatamab as a potential new standard of care for HER2-positive gastroesophageal cancer. If approved, zanidatamab would represent the first bispecific antibody targeting HER2 in gastroesophageal cancer. The therapy’s mechanism of action may also have implications for other HER2-positive cancers, including breast cancer.
Zanidatamab plus chemotherapy demonstrated a 44% reduction in the risk of disease progression or death compared to trastuzumab plus chemotherapy in patients with HER2-positive gastroesophageal adenocarcinoma.
— HERIZON-GEA-01 Study Results, The New England Journal of Medicine, 2026
Key takeaways
- Zanidatamab plus chemotherapy improved progression-free survival by 56% at 18 months versus standard treatment (HERIZON-GEA-01 trial)
- The bispecific antibody targets two distinct HER2 epitopes simultaneously
- Safety profile was manageable with low rates of cardiac dysfunction across both treatment arms (NEJM study)
- Results support regulatory submissions for a potential new standard of care in HER2-positive gastroesophageal cancer
Frequently asked questions
What makes zanidatamab different from existing HER2-targeted therapies?
Zanidatamab is a bispecific antibody that simultaneously binds to two distinct regions of the HER2 receptor, according to the NEJM study, compared to conventional antibodies like trastuzumab that target a single epitope.
How many patients were enrolled in the HERIZON-GEA-01 trial?
The HERIZON-GEA-01 trial enrolled 710 patients across multiple international sites according to the study published in The New England Journal of Medicine.
What were the main efficacy outcomes?
The trial showed zanidatamab plus chemotherapy achieved a median progression-free survival of 12.5 months compared to 8.5 months for trastuzumab plus chemotherapy, with a hazard ratio of 0.56 (95% CI, 0.45-0.70) according to the NEJM study results.
The HERIZON-GEA-01 trial results published in The New England Journal of Medicine mark a significant advancement in the treatment of HER2-positive gastroesophageal cancer. As regulatory reviews proceed, the medical community will be watching closely to see how zanidatamab might reshape treatment paradigms for this challenging malignancy.
Source: Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer, The New England Journal of Medicine, 2026
